GlassScriptPhysician profile
Praveen Pathak
NPI 1386613867
$2,632.88
in general payments reported to CMS, 2019-2025
25 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,610 · 2020: $370 · 2021: $298 · 2022: $15.01 · 2023: $178 · 2024: $35.64 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $720.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $252.19 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $248.83 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $237.09 | 2019-2021 | |
| Abbvie INC. | $225.33 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $117.05 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $117.03 | 2019-2020 | |
| Indivior INC. | $86.70 | 2019-2020 | |
| Lundbeck LLC | $77.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $55.77 | 2019 | |
| Validus Pharmaceuticals LLC | $49.84 | 2019 | |
| Bioxcel Therapeutics, INC. | $47.49 | 2023 | Igalmi |
| Shire North American Group INC | $46.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.97 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $45.51 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $44.98 | 2019-2020 | |
| Adlon Therapeutics L.P. | $42.20 | 2019-2020 | |
| Allergan, INC. | $33.70 | 2019-2020 | |
| Neos Therapeutics, LP | $29.00 | 2019 | |
| Merck Sharp & Dohme LLC | $23.65 | 2019 | |
| Orexo US, INC. | $21.51 | 2019 | |
| Alkermes, INC. | $19.25 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.25 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.23 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praveen Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.